Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses

Background This study aimed to evaluate the safety and effectiveness of the BNT162b2 vaccine in immunocompromised adolescents and young adults. Research design and methods The study conducted a meta-analysis of post-marketing studies examining BNT162b2 vaccination efficacy and safety among immunocom...

Full description

Bibliographic Details
Main Authors: Patrick DMC Katoto, Mireille AM Kakubu, Jacques L. Tamuzi, Amanda S. Brand, Adaeze Ayuk, Liliane N. Byamungu, Charles S. Wiysonge, Glenda Gray
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Expert Review of Vaccines
Subjects:
sars-cov-2
children
comorbidity
immunization
post marketing
Online Access:http://dx.doi.org/10.1080/14760584.2023.2204154

Internet

http://dx.doi.org/10.1080/14760584.2023.2204154

Similar Items